scholarly journals Risk Factors for Weight Gain Following Switch to Integrase Inhibitor–Based Antiretroviral Therapy

2020 ◽  
Vol 71 (9) ◽  
pp. e471-e477 ◽  
Author(s):  
Jordan E Lake ◽  
Kunling Wu ◽  
Sara H Bares ◽  
Paula Debroy ◽  
Catherine Godfrey ◽  
...  

Abstract Background Treatment initiation with integrase strand transfer inhibitors (INSTIs) has been associated with excess weight gain. Whether similar gains are seen after switch to INSTIs among virologically suppressed persons is less clear. We assessed pre/post-INSTI weight changes from AIDS Clinical Trials Group participants (A5001 and A5322). Methods Participants who were in follow-up from 1997–2017 and switched to INSTI-based antiretroviral regimens were included. Piecewise linear mixed-effects models adjusting for age, sex, race/ethnicity, baseline BMI, nadir and current CD4+ T-cell count, smoking, diabetes and follow-up time with suppressed HIV-1 RNA examined weight and waist circumference change before and after first switch to INSTIs. Linear spline models with a single knot at time of switch accounted for nonlinear trends. Results The 972 participants who switched to INSTIs were 81% male and 50% nonwhite with a median age at switch of 50 years, CD4+ T-cell count 512 cells/μL, and BMI 26.4 kg/m2. Restricting to persons with suppressed HIV-1 RNA at switch (n = 691), women, blacks, and persons ≥60 years experienced greater weight gain in the 2 years after versus before switch. In adjusted models, white or black race, age ≥60, and BMI ≥30 kg/m2 at switch were associated with greater weight gain following switch among women; age ≥60 was the greatest risk factor among men. Trends for waist circumference were similar. Conclusions Yearly weight gain increased following switch to INSTIs, particularly for women, blacks, and persons aged ≥60. Concomitant increases in waist circumference suggest that this weight gain is associated with an increase in fat mass.

AIDS ◽  
2002 ◽  
Vol 16 (13) ◽  
pp. 1832-1834 ◽  
Author(s):  
Susan Swindells ◽  
Daniel G. Cobos ◽  
Nancy Lee ◽  
Elizabeth A. Lien ◽  
Ann P. Fitzgerald ◽  
...  

2013 ◽  
Vol 85 (10) ◽  
pp. 1687-1691 ◽  
Author(s):  
Man-Qing Liu ◽  
Li Tang ◽  
Wen-Hua Kong ◽  
Ze-Rong Zhu ◽  
Jin-Song Peng ◽  
...  

AIDS ◽  
2006 ◽  
Vol 20 (16) ◽  
pp. 2033-2041 ◽  
Author(s):  
Marco Marziali ◽  
Wladimiro De Santis ◽  
Rossella Carello ◽  
Wilma Leti ◽  
Antonella Esposito ◽  
...  

2017 ◽  
Vol 9 (1) ◽  
pp. 2017049 ◽  
Author(s):  
Lassina TRAORE ◽  
Ouéogo NIKIEMA ◽  
Abdoul Karim OUATTARA ◽  
Tegwindé Rébéca COMPAORE ◽  
Serge Théophile SOUBEIGA ◽  
...  

Epstein Barr Virus (EBV) and Human Herpes Virus 6 (HHV-6) are responsible for severe diseases, particularly in immunocompromised persons. There are poor data on the infection with these opportunistic viruses in Burkina Faso.The purpose of this study is to characterize EBV and HHV-6 subtypes and to assess their impact on CD4 T cell count, HIV-1 viral load and antiretroviral treatment in people living with HIV-1.The study population consisted of 238 HIV-positive patients with information on CD4 count, HIV-1 viral load and HAART. Venous blood samples collected on EDTA tubes were used for EBV and HHV-6 Real Time PCR subtyping.An infection rate of 6.7% (16/238) and 7.1% (17/238) were found respectively for EBV and HHV-6 in the present study. Among EBV infections, similar prevalences were noted for both subtypes (3.9% [9/238] for EBV-1 vs 4.6% [11/238] for EBV-2) with 2.1% (5/238) of co-infection. HHV-6A infection represented 6.3% (15/238) of the study population against 5.0% (12/238) for HHV-6B. . EBV-2 infection was significantly higher in patients with CD4 count ≥ 500 compared to those with CD4 count less than 500 cells (1.65% vs 8.56%, p = 0,011). The prevalence of EBV and HHV-6 infections were almost similar in HAART-naive and HAART-experienced patients.The present study provides information on the prevalence of EBV and HHV-6 subtypes in people living with HIV-1 in Burkina Faso. The study also suggests that HAART treatment has no effect on infection with these opportunistic viruses in people living with HIV-1.


2009 ◽  
Vol 76B (4) ◽  
pp. 249-260 ◽  
Author(s):  
Edouard Tuaillon ◽  
Yassine Al Tabaa ◽  
Vincent Baillat ◽  
Michel Segondy ◽  
Marie-Christine Picot ◽  
...  

2017 ◽  
Vol 2 (Suppl 2) ◽  
pp. A33.2-A34
Author(s):  
Iheanyi Okonko ◽  
Phillip Okerentugba ◽  
Oluyinka Opaleye ◽  
Ezinwanne Awujo ◽  
Nnenna Frank-Peterside

2009 ◽  
Vol 52 (5) ◽  
pp. 659-661 ◽  
Author(s):  
Hector Bolivar ◽  
Rebeca Geffin ◽  
Gabriel Manzi ◽  
Margaret A Fischl ◽  
Vera Holzmayer ◽  
...  

Intervirology ◽  
2015 ◽  
Vol 58 (3) ◽  
pp. 155-159 ◽  
Author(s):  
Matthieu Sechet ◽  
Catherine Roussel ◽  
Jean-Luc Schmit ◽  
Carlo Saroufim ◽  
Kamel Ghomari ◽  
...  

Objective: The aim of this study was to evaluate tropism prediction performances of three algorithms [geno2pheno false-positive rate 10% (G2P10), position-specific scoring matrix (PSSM) and a combination of the 11/25 and net charge rules] and to investigate the viral and host factors potentially involved in the X4 or R5 prediction in human immunodeficiency virus-1 (HIV-1) patients. Methods: Viral tropism was determined in 179 HIV-1-infected patients eligible for CCR5 antagonist therapy. HIV-1 RNA or DNA was extracted and amplified for env gp120 sequencing. In parallel, demographic, viral, immunological and clinical determinants were analyzed. Results: According to the G2P10 algorithm, 48 patients harbored X4 or X4R5 virus. The tropism prediction was concordant for 87.7 and 88.2% of samples when comparing G2P10 with PSSM or with a combination of the 11/25 and net charge rules, respectively. X4 prediction was significantly associated with more than 35 amino acids in the V3 domain (p < 0.0001) and loss of an N-linked glycosylation site (p < 0.0001). Of the factors studied, only the nadir CD4 T-cell count was significantly associated with X4 tropism (p = 0.01). Conclusion: We determined that the X4 virus detection is closely linked to the nadir CD4 T-cell count below 100 cells/mm3 that must be taken into account when considering a CCR5 antagonist therapy switch.


2017 ◽  
Vol 35 (3) ◽  
pp. 174-178 ◽  
Author(s):  
Omar Jesus Benmarzouk-Hidalgo ◽  
Almudena Torres-Cornejo ◽  
Alicia Gutierrez-Valencia ◽  
Pompeyo Viciana ◽  
Luis Fernando López-Cortés

Sign in / Sign up

Export Citation Format

Share Document